alkaloid/neoplasms

This application corresponds to my German Patent application No. P 31 28 018.8, filed on July 13, 1981 which is relied upon and incorporated by reference herein. FIELD OF THE INVENTION The invention is directed to a method for diagnosing and for therapeutic treatment of tumors and infectious

FIELD OF INVENTION This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions. BACKGROUND OF INVENTION Autophagy is a cellular

FIELD OF INVENTION This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions. BACKGROUND OF INVENTION Autophagy is a cellular

FIELD OF INVENTION This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions. BACKGROUND OF INVENTION Autophagy is a cellular

FIELD OF INVENTION This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions. BACKGROUND OF INVENTION Autophagy is a cellular

FIELD OF INVENTION This invention relates to a group of novel autophagy enhancers, namely liensinine, isoliensinine, dauricine, cepharanthine, hernandezine and thalidezine, and their use thereof in treating cancers and neurodegenerative conditions. BACKGROUND OF INVENTION Autophagy is a cellular

This application is a 35 U.S.C. 371 national stage filing and claims priority to PCT Application No. PCT/IN2014/000201, entitled "Novel Chromone Alkaloid Dysoline for the Treatment of Cancer and Inflammatory Disorders" filed on Mar. 31, 2014, which claims priority to Indian Application No.

BACKGROUND ART Vinca alkaloids, originally isolated from the periwinkle plant [Vinca rosea Linn., now Cantharanthus roseus (L.) G. Don] are a family of indole-indoline dimeric compounds that contain a four-ring system containing an indole linked to a five-ring system containing an indoline. Two of

FIELD OF THE INVENTION This invention relates to the fields of biochemistry and medicine, and particularly to a pharmaceutical preparation which includes liposome-entrapped water soluble drug formulations, and methods of using such formulations to control the delivery of encapsulated agents to

FIELD OF THE INVENTION This invention relates to the fields of biochemistry and medicine, and particularly to a pharmaceutical preparation which includes liposome-entrapped water soluble drug formulations, and methods of using such formulations to control the delivery of encapsulated agents to

FIELD OF THE INVENTION This invention relates to the fields of biochemistry and medicine, and particularly to a pharmaceutical preparation which includes liposome-entrapped water soluble drug formulations, and methods of using such formulations to control the delivery of encapsulated agents to

The present invention is in the field of biochemistry and pharmacology. Specifically, the present invention relates to methods for treating cancers and malignancies by administering a pharmaceutically effective amount of a diiodo thyronine analogue having no significant hormonal activity and a vinca

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of vinca alkaloids in combatting tumors. 2. Discussion of the Background The dimeric alkaloids, vincristine and vinblastine, containing indol-indoline moieties from Catharanthus species are widely used as

This application is a National Stage Application of PCT/EP2013/064048 filed Jul. 3, 2013, which claims priority from European Patent Application No. 12175724.9, filed on Jul. 10, 2012. The priority of both said PCT and European Patent Application are claimed. Each of the prior mentioned applications

BACKGROUND Monoamine oxidase (MAO) inhibitors can regulate the level of monoamines and their neurotransmitter release in different brain regions and in the body (including dopamine, norepinephrine, and serotonin). MAO inhibitors (MAOI) can thereby affect the modulation of neuroendocrine function,